Latest news articles

Added 15 days ago Drug news

NICE now recommends Crysvita to treat X-linked hypophosphatemia.- Kyowa Hakko Kirin + Ultragenyx.

The National Institute for Health and Care Excellence (NICE) has now recommended Crysvita (burosumab) from Kyowa Hakko Kirin within its...

Added 1 month ago Drug news

FDA accepts filing of ALXN 1210 to treat paroxysmal nocturnal hemoglobinuria.- Alexion Pharma.

Alexion Pharmaceuticals, Inc.v announced that the FDA has accepted for review the Company’s Biologics License Application (BLA) for approval of...

Added 1 month ago Drug news

LentiGlobin for the treatment of transfusion-dependent beta-thalassemia and a non-beta0/beta0 genotype, was granted an accelerated assessment by the CHMP.- bluebird bio Inc.

bluebird bio, Inc. announced that its investigational LentiGlobin gene therapy for the treatment of adolescent and adult patients with transfusion-dependent...

Search all news articles for Deficiency and other anaemia
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Oral Anticoagulation Reversal

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.

Load more

Guidelines

Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines

Anaemia and iron deficiency are frequent complications in patients with solid tumours or haematological malignancies, particularly in patients treated with chemotherapeutic agents.

Added 5 months ago

Guidelines for the diagnosis and management of adult aplastic anaemia

This is a comprehensive but pragmatic new guideline and focuses on the accurate diagnosis, delineation of severity types and subsequent management of this rare haematological condition.

Added 2 years ago

The diagnosis and management of primary autoimmune haemolytic anaemia

The objective of this guideline is to provide healthcare professionals with guidance on the management of patients with primary autoimmune haemolytic anaemia (AIHA).

Added 6 months ago

Search all guidelines for Deficiency and other anaemia
 

Journal articles

Causal relationship between hypoalbuminemia and acute kidney injury.

Our meta-analysis published in 2010 provided evidence that low levels of serum albumin (hypoalbuminemia) are a significant independent predictor of acute kidney injury (AKI) and death following AKI.

Added 1 year ago

Could testosterone therapy in hypogonadal men ameliorate anemia, a cardiovascular risk factor? An observational, 54-week cumulative registry study.

In this study we investigated if testosterone undecanoate attenuates anemia and the risk of cardiovascular disease in patients with hypogonadism.

Added 1 year ago

Treatment of Atypical Hemolytic-Uremic Syndrome in the Era of Eculizumab.

Hemolytic-uremic syndrome (HUS) is the triad of microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and acute kidney injury (AKI); the main cause of multi-organ failure is related to thrombotic microangiopathy (TMA).

Added 1 year ago

Search all journal articles for Deficiency and other anaemia
 

Clinical trials

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia (BELIEVE)

This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) plus Best supportive care (BSC) versus placebo plus BSC in...

Added 2 months ago

A Study Evaluating the Efficacy and Safety of LentiGlobin BB305 Drug Product in Beta-Thalassemia Major and Sickle Cell Disease

This is a Phase 1/2, open label, safety, and efficacy study of the administration of LentiGlobin BB305 Drug Product to subjects with either beta-thalassemia major or severe sickle cell disease (SCD).

Added 5 years ago

Search all clinical trials for Deficiency and other anaemia
 

CME

Facial conditions: illustrated

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
0
Registration required
1
Subscription fee
0
Search all CME for Deficiency and other anaemia